Novartis hits acquisition trail

Swiss drugmaker Novartis has announced 5.65bn euros ($7.4bn; Novartis said that it would be able to make cost savings of about $200m a year following the acquisitions. Novartis' shares rose 1% to 57.85 Swiss francs in early trading. There are more than 150 generic drugmakers worldwide and analysts have predicted consolidation in a market that they call fragmented.